Zai Lab's Zoci Shows 40% Response Rate in Trial of Previously Treated Extrapulmonary Neuroendocrine Cancers

Bitget2026/11/05 14:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zai Lab’s Phase 1b/2 trial showed durable tumor responses to zocilurtatug pelitecan in previously treated advanced extrapulmonary neuroendocrine carcinomas.
Updated results will be presented November 6, 2026, at the North American Neuroendocrine Tumor Society symposium in Las Vegas.
Treatment showed a manageable safety profile, with few treatment-related discontinuations and no treatment-related deaths.
The company plans to pursue potential accelerated approval based on its single-arm expansion study, with topline data expected in 2027.
A global Phase 3 trial evaluating the drug as first-line maintenance monotherapy is expected to begin in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050900BIZWIRE_USPR_____20261105_BW430679) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zai Lab's Zoci Shows 40% Response Rate in Trial of Previously Treated Extrapulmonary Neuroendocrine Cancers

You may also like

Crypto prices